Inflammation as a therapeutic target in heart failure with preserved ejection fraction

Zhen Hui Peh; Adel Dihoum; Dana Hutton; J Simon C Arthur; Graham Rena; Faisel Khan; Chim C Lang; Ify R Mordi

doi:10.3389/fcvm.2023.1125687

Inflammation as a therapeutic target in heart failure with preserved ejection fraction

Front Cardiovasc Med. 2023 Jun 29:10:1125687. doi: 10.3389/fcvm.2023.1125687. eCollection 2023.

Authors

Zhen Hui Peh¹, Adel Dihoum², Dana Hutton¹, J Simon C Arthur³, Graham Rena⁴, Faisel Khan⁵, Chim C Lang², Ify R Mordi²

Affiliations

¹ School of Medicine, University of Dundee, Ninewells Hospital, Dundee, United Kingdom.
² Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, United Kingdom.
³ Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, United Kingdom.
⁴ Division of Cellular Medicine, School of Medicine, University of Dundee, Dundee, United Kingdom.
⁵ Division of Systems Medicine, School of Medicine, University of Dundee, Dundee, United Kingdom.

Abstract

Heart failure with preserved ejection fraction (HFpEF) accounts for around half of all cases of heart failure and may become the dominant type of heart failure in the near future. Unlike HF with reduced ejection fraction there are few evidence-based treatment strategies available. There is a significant unmet need for new strategies to improve clinical outcomes in HFpEF patients. Inflammation is widely thought to play a key role in HFpEF pathophysiology and may represent a viable treatment target. In this review focusing predominantly on clinical studies, we will summarise the role of inflammation in HFpEF and discuss potential therapeutic strategies targeting inflammation.

Keywords: HFpEF; cardiometabolic; heart failure; inflammation; interleukins.

Publication types

Review

Grants and funding

This work has been supported by a research grant from Tenovus Scotland (T20/58).